Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.

@article{Shamji2017BiomarkersFM,
  title={Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.},
  author={M H Shamji and Jasper H. Kappen and M{\"u}beccel Akdis and Erika Jensen-Jarolim and E F Knol and Joerg Kleine-Tebbe and Barbara Bohle and Adam M. Chaker and Stephen John Till and Rudolf Valenta and Lars K{\ae}rgaard Poulsen and Moises A. Calder{\'o}n and Pascal Demoly and Oliver Pfaar and Lars Jacobsen and Stephen R. Durham and Carsten B. Schmidt-Weber},
  journal={Allergy},
  year={2017},
  volume={72 8},
  pages={1156-1173}
}
BACKGROUND Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma. It is important to note that due to the complex interaction between patient, allergy triggers, symptomatology and vaccines used for AIT, some patients do not respond optimally to the treatment. Furthermore, there are no validated or generally accepted candidate biomarkers that are predictive of the clinical response to AIT. Clinical management of patients receiving AIT… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 29 times over the past 90 days. VIEW TWEETS